mar, 26 mars 2024
Hemotune’s innovative blood purification platform, HemoSystem, propels into clinical trials with a CHF 14 million Series B2 boost.
Hemotune AG, a Swiss biotech compmany, has concluded its Series B2 funding round, raising CHF 14 million, they claim in a press release. This pivotal financial injection, spearheaded by Belmondo and supported by stalwarts such as VP Venture Partners, heralds in the next stage of clinical trials for its groundbreaking HemoSystem blood purification platform.
The HemoSystem, uses nanoengineered magnetic beads. By eliminating large biomolecules directly from the bloodstream, it offers a novel avenue for multi-target treatments unattainable through conventional drug therapies.
Initially targeting the formidable challenge of sepsis-related immune suppression—a condition responsible for approximately 11 million fatalities annually and imposing a significant economic strain.
Lukas Langenegger, CEO and co-founder of Hemotune AG, expressed profound pride in the team’s milestone achievement of preclinical development and clinical trials.
Dr. Darius Madjdpour, the visionary founder at Belmondo, lauded Hemotune’s stellar performance over the past seven years, culminating in a platform technology with unparalleled potential in the medical field.
The HemoSystem’s capacity to address a spectrum of diseases and enable novel therapies was a key motivator for Belmondo’s lead role in this funding round.
Pascal Winnen, CEO of HEMEX, reaffirmed the CRO’s dedication to supporting Hemotune’s novel strategy to combat septic shock, recognising the technology’s vast potential to filter detrimental agents from the bloodstream selectively.
French 
English 
German 
Spanish 
Arabic